Abstract
Melanoma cell lines are useful tools for the analysis of tumor-specific lymphocytes which are injected to patients treated by adoptive immunotherapy. So they have been established previously (with an efficacy of 47%) in Roswell Park Memorial Institute (RPMI) medium enriched with fetal calf serum (FCS). In order to improve the probability of establishing melanoma cell lines, we compared two FCS-free media with the original FCS medium. Ten melanoma-invaded lymph nodes were tested for their ability to grow in three different culture media: RPMI with FCS; RPMI with human serum (HS); serum-free X-vivo 15 (X15). For each medium, we compared the following criteria: percentage of lines obtained; period of establishment; cell morphology; expression of melanoma-associated antigens and surface molecules. More cell lines were obtained with HS and X15 media compared to FCS medium (7/10, 5/10 and 4/10, respectively). The time period to establish a stable line was similar for the three media. No morphological differences were observed in cells derived from the same tumor sample in the different media. With the X15 medium, cells generally expressed lower levels of melanocytic differentiation antigens and surface molecules. The growth of melanoma cell lines in FCS-free culture media appears possible and advantageous, with an increased probability of obtaining autologous tumor cell lines. Furthermore the cells obtained could be used as multiple antigenic sources in active or adoptive immunotherapy protocols.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bruserud O, Tronstad KJ, Berge R (2005) In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum. J Cancer Res Clin Oncol 131:377–384. doi:10.1007/s00432-004-0650-z
Dillman RO, Beutel L, Nayak S, Depriest C, Selvan S, Schiltz P (2005) Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes? Cancer Biother Radiopharm 20:373–378. doi:10.1089/cbr.2005.20.373
Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666–675. doi:10.1038/nrc1167
Gervois N, Heuze F, Diez E, Jotereau F (1990) Selective expansion of a specific anti-tumor CD8 + cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol 20:825–831
Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, Jotereau F, Labarriere N (2008) MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med 205:2673–2682. doi:10.1084/jem.20081356
Labarriere N, Diez E, Pandolfino MC, Viret C, Guilloux Y, Le Guiner S, Fonteneau JF, Dreno B, Jotereau F (1997) Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J Immunol 158:1238–1245
Labarrière N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dréno B, Jotereau F (2002) Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother CII 51:532–538. doi:10.1007/s00262-002-0313-3
Lacreusette A, Nguyen J-M, Pandolfino M-C, Khammari A, Dreno B, Jacques Y, Godard A, Blanchard F (2007) Loss of oncostatin M receptor beta in metastatic melanoma cells. Oncogene 26:881–892. doi:10.1038/sj.onc.1209844
Lacreusette A, Lartigue A, Nguyen J-M, Barbieux I, Pandolfino M-C, Paris F, Khammari A, et al. (2008) Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes. J Pathol 216:451–459. doi:10.1002/path.2416
Lacreusette A, Barbieux I, Nguyen JM, Pandolfino MC, Dréno B, Jacques Y, Godard A, Blanchard F (2009) Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells. J Pathol 217:665–676. doi:10.1002/path.2490
Le Dréan E, Gervois N, Diez E, Semana G, Dreno B, Jotereau F (1995) HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4 + melanoma-infiltrating lymphocytes. Eur J Immunol 25:2732–2736
Le Guiner S, Le Dréan E, Labarrière N, Fonteneau JF, Viret C, Diez E, Jotereau F (1998) LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal. Eur J Immunol 28:1322–1331
Lotem M, Yehuda-Gafni O, Butnaryu E, Drize O, Peretz T, Abeliovich D (2003) Cytogenetic analysis of melanoma cell lines: subclone selection in long-term melanoma cell cultures. Cancer Genet Cytogenet 142:87–91
Pandolfino MC, Labarrière N, Tessier MH, Cassidanius A, Bercegeay S, Lemarre P, Dehaut F, Dréno B, Jotereau F (2001) High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement. Cancer Immunol Immunother CII 50:134–140
Panelli MC, Riker A, Kammula U, Wang E, Lee KH, Rosenberg SA, Marincola FM (2000) Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol 164:495–504
Sulit HL, Golub SH, Irie RF, Gupta RK, Grooms GA, Morton D (1976) Human tumor cells grown in fetal calf serum and human serum: influences on the tests for lymphocyte cytotoxicity, serum blocking and serum arming effects. Int J Cancer 17:461–468
Vogl A, Sartorius U, Vogt T, Roesch A, Landthaler M, Stolz W, Becker B (2005) Gene expression profile changes between melanoma metastases and their daughter cell lines: implication for vaccination protocols. J Invest Dermatol 124:401–404. doi:10.1111/j.0022-202X.2004.23603.x
Zhou X, Jun DY, Thomas AM, Huang X, Huang L, Mautner J, Mo W, Robbins PF, Pardoll DM, Jaffee EM (2005) Diverse CD8 + T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res 65:1079–1088
Zitvogel L, Angevin E, Tursz T (2000) Dendritic cell-based immunotherapy of cancer. Ann Oncol 11 Suppl 3:199–205
Acknowledgments
We would like to thank M. Yviquiel and S. Peltier for their technical support in semi-quantitative RT–PCR. We also would like to acknowledge C. Holmes who translated parts of this article. This paper is supported by Cancer Immunotherapy SIXTH FRAMEWORK PROGRAMME.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pandolfino, M.C., Saïagh, S., Knol, A.C. et al. Comparison of three culture media for the establishment of melanoma cell lines. Cytotechnology 62, 403–412 (2010). https://doi.org/10.1007/s10616-010-9286-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-010-9286-9